Cancer Clinical Trials System Needs Comprehensive Review, NCI Director Says
NCI, Dialogue Plan A National Tissue Bank
Group Chairmen Criticize NCI Budget Priorities
Groups Point to NCI Restrictions As Source Of Problems, Discuss Prioritizing Trials
Kimes, Lenfant, To Retire
Cancer.gov Knocked Offline By Theft Of Routers
Six Centers Win Grants
PHS Plans Revitalization of Commissioned Corps
Funding Opportunities Listed (12-page issue).
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation
- FDA’s OCE publishes three final guidances to increase clinical trial enrollment
